Company Overview - Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company focused on developing proprietary technology to enhance the immune system's ability to fight cancer [5] - The company utilizes allogeneic stem cells to deliver oncolytic viruses for various oncology indications, including high-grade gliomas and solid tumors [5] - Calidi's innovative platforms aim to protect, amplify, and potentiate oncolytic viruses, potentially improving efficacy and patient safety [5] Industry Context - Approximately 20 million people are diagnosed with cancer each year, with nearly 10 million deaths globally, a figure expected to rise significantly by 2050 [3] - The American Cancer Society projects that annual cancer diagnoses will reach 35 million by 2050, highlighting the urgent need for more effective therapies [3] - The demand for innovation in cancer treatment presents significant market opportunities for companies like Calidi Biotherapeutics [3][4] Technological Approach - Calidi Biotherapeutics is developing a next-generation platform that delivers genetic medicines directly to primary and metastatic tumors using engineered viruses [4] - The company's dual approach aims to treat or prevent metastatic disease, positioning it among leading biotech innovators [4]